Encompass Health Corporation (NYSE:EHC) Receives $127.00 Average Price Target from Analysts

Encompass Health Corporation (NYSE:EHC - Get Free Report) has earned an average rating of "Buy" from the nine research firms that are presently covering the stock, Marketbeat reports. Seven research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $127.00.

EHC has been the subject of several research analyst reports. UBS Group upped their price objective on shares of Encompass Health from $117.00 to $130.00 and gave the stock a "buy" rating in a report on Monday, April 28th. KeyCorp lifted their target price on Encompass Health from $122.00 to $135.00 and gave the stock an "overweight" rating in a report on Tuesday, May 27th. Truist Financial reaffirmed a "buy" rating and set a $135.00 price objective (up from $116.00) on shares of Encompass Health in a research note on Monday, April 28th. Stephens upgraded Encompass Health from an "overweight" rating to a "strong-buy" rating and set a $135.00 target price on the stock in a research note on Thursday, June 5th. Finally, Wall Street Zen lowered shares of Encompass Health from a "strong-buy" rating to a "buy" rating in a research note on Friday, June 6th.

Encompass Health Stock Performance

NYSE:EHC traded up $0.55 during mid-day trading on Tuesday, hitting $122.09. The stock had a trading volume of 1,019,460 shares, compared to its average volume of 763,824. The company has a current ratio of 1.06, a quick ratio of 1.06 and a debt-to-equity ratio of 0.81. The company has a 50 day simple moving average of $117.22 and a 200-day simple moving average of $104.49. The stock has a market capitalization of $12.31 billion, a price-to-earnings ratio of 25.22, a P/E/G ratio of 2.45 and a beta of 0.89. Encompass Health has a 52 week low of $82.74 and a 52 week high of $123.13.

Encompass Health (NYSE:EHC - Get Free Report) last issued its quarterly earnings data on Thursday, April 24th. The company reported $1.37 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.19 by $0.18. Encompass Health had a return on equity of 17.63% and a net margin of 8.97%. The business had revenue of $1.46 billion during the quarter, compared to the consensus estimate of $1.43 billion. During the same period in the previous year, the firm posted $1.12 earnings per share. The business's revenue was up 10.6% on a year-over-year basis. On average, research analysts expect that Encompass Health will post 4.8 earnings per share for the current fiscal year.

Encompass Health Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, July 15th. Investors of record on Tuesday, July 1st will be paid a dividend of $0.17 per share. This represents a $0.68 annualized dividend and a yield of 0.56%. The ex-dividend date is Tuesday, July 1st. Encompass Health's payout ratio is currently 14.05%.

Insiders Place Their Bets

In related news, EVP John Patrick Darby sold 10,000 shares of the stock in a transaction dated Tuesday, April 29th. The shares were sold at an average price of $114.79, for a total transaction of $1,147,900.00. Following the completion of the sale, the executive vice president now owns 79,710 shares in the company, valued at $9,149,910.90. This trade represents a 11.15% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Mark J. Tarr sold 118,384 shares of Encompass Health stock in a transaction that occurred on Tuesday, May 20th. The shares were sold at an average price of $121.53, for a total transaction of $14,387,207.52. Following the completion of the transaction, the chief executive officer now owns 527,070 shares of the company's stock, valued at $64,054,817.10. This trade represents a 18.34% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 132,663 shares of company stock worth $16,034,082 in the last ninety days. Insiders own 2.00% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. WPG Advisers LLC acquired a new position in shares of Encompass Health in the 1st quarter valued at $27,000. Colonial Trust Co SC acquired a new position in shares of Encompass Health during the fourth quarter worth about $29,000. Transce3nd LLC acquired a new stake in shares of Encompass Health in the fourth quarter valued at approximately $40,000. CBIZ Investment Advisory Services LLC boosted its stake in shares of Encompass Health by 38.7% during the 4th quarter. CBIZ Investment Advisory Services LLC now owns 455 shares of the company's stock worth $42,000 after buying an additional 127 shares during the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. grew its stake in Encompass Health by 749.0% in the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 416 shares of the company's stock valued at $42,000 after purchasing an additional 367 shares in the last quarter. 97.25% of the stock is currently owned by institutional investors.

About Encompass Health

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.